Trials No Longer Recruiting

The following MDS clinical trials are no longer open to recruitment in the UK.

Clinical trials are expected to recruit patients for a finite period of time. Each trial has an expected recruitment target, i.e. a specific number of patients needed to participate in the trial in order for the results of the trial to be meaningful and answer all of the proposed questions. Once this target is achieved, the trial is closed to recruitment and the data obtained from the trial is analysed and interpreted. It can take several months for this analysis to be completed. The final results are often published in international journals and/or presented at a scientific meeting.

Please visit the following page for Currently Open MDS Clinical Trials.

If you'd like more information about what is a clinical trial and how it is conducted, please go to this section

Learn more about the latest MDS research

MDS Trials No Longer Recruiting

Durvalumab in Previously Untreated Patients

  1. SUB-TYPE OF MDS: Higher risk MDS and also elderly patients (age ≥ 65 years) with Acute Myeloid Leukaemia
  2. SEVERITY OF MDS: Intermediate –2 or High Risk
  3. NAME OF DRUG: Subcutaneous Azacitidine and Durvalumab, which activates the immune system to have a response against tumor cells.
Read full story


  1. SUB-TYPE OF MDS: Patients with Acute Myeloid Leukemia that has returned after a period of improvement (relapsed) or have not responded to previous treatment (refractory).
  2. SEVERITY OF MDS: Higher Risk
  3. NAME OF DRUG: Anti-CD47 monoclonal antibody, Hu5F9-G4 (target therapy that blocks the growth of cancer cells)
Read full story

Eltrombopag for MDS patients

  1. SUB-TYPE OF MDS: MDS patients who are platelet transfusion dependent
  2. SEVERITY OF MDS: intermediate 1 & 2 or high risk
  3. NAME OF DRUG: Eltrombopag, Promacta™/Revolade™
Read full story
Free donations by shopping